Colinz Laboratories Ltd
₹ 41.0
-1.98%
04 Jul
- close price
About
Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations[1]
Key Points
- Market Cap ₹ 18.8 Cr.
- Current Price ₹ 41.0
- High / Low ₹ 88.7 / 41.0
- Stock P/E 37.5
- Book Value ₹ 20.7
- Dividend Yield 0.00 %
- ROCE 6.72 %
- ROE 5.43 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 46.4 to 36.9 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -2.81% over past five years.
- Company has a low return on equity of 5.73% over last 3 years.
- Working capital days have increased from 46.9 days to 109 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.41 | 7.88 | 8.10 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.53 | |
| 7.07 | 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.52 | 6.49 | 6.04 | |
| Operating Profit | 0.34 | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.49 |
| OPM % | 4.59% | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 7.50% |
| 0.13 | 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.19 | 0.17 | 0.15 | 0.28 | 0.30 | |
| Interest | 0.08 | 0.12 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.09 | 0.08 | 0.05 | 0.04 | 0.04 |
| Depreciation | 0.26 | 0.30 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.20 | 0.13 | 0.13 | 0.13 |
| Profit before tax | 0.13 | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.60 | 0.65 | 0.62 |
| Tax % | 46.15% | 35.71% | 40.00% | -27.27% | -53.33% | 26.67% | 27.78% | 16.00% | 29.17% | 23.33% | 26.15% | 19.35% |
| 0.07 | 0.10 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.50 | |
| EPS in Rs | 0.15 | 0.22 | 0.20 | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 1.01 | 1.07 | 1.09 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 31% |
| 3 Years: | 14% |
| TTM: | 2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 38% |
| 3 Years: | 16% |
| 1 Year: | -47% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.78 | 2.62 | 2.71 | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.96 |
| 1.88 | 2.53 | 1.80 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.64 | |
| 1.79 | 1.97 | 1.70 | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 1.82 | 1.84 | 1.70 | |
| Total Liabilities | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 |
| 3.72 | 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.70 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.32 | 0.29 | 0.29 | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.04 |
| 5.95 | 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 7.86 | 8.76 | 9.08 | |
| Total Assets | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.64 | 0.09 | 0.58 | 0.06 | 0.34 | 0.12 | 0.58 | 2.16 | 0.47 | 0.40 | 1.03 | -1.45 | |
| 0.00 | 0.03 | 0.00 | -0.01 | -0.11 | -0.01 | -0.04 | -0.16 | -0.03 | 0.01 | 0.01 | -0.23 | |
| -0.37 | 0.45 | -0.73 | -0.03 | 0.01 | 0.02 | 0.06 | 0.08 | 0.09 | 0.11 | 0.23 | 0.24 | |
| Net Cash Flow | 0.27 | 0.57 | -0.16 | 0.02 | 0.24 | 0.12 | 0.60 | 2.07 | 0.52 | 0.52 | 1.27 | -1.45 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.51 | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 | 36.89 |
| Inventory Days | 188.53 | 288.96 | 232.18 | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 | 149.17 | 134.31 | 136.22 |
| Days Payable | 93.17 | 116.24 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 | 103.15 | 94.81 | 94.31 |
| Cash Conversion Cycle | 160.87 | 235.25 | 232.35 | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 | 103.71 | 84.15 | 78.81 |
| Working Capital Days | 89.65 | 110.24 | 100.04 | 105.65 | 92.30 | 122.15 | 97.43 | 58.66 | 35.09 | 25.01 | 6.75 | 109.00 |
| ROCE % | 2.51% | 3.20% | 3.23% | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% | 8.08% | 7.70% | 6.72% |
Documents
Announcements
-
Declaration Of Non-Applicability Of Reg. 32 Of The SEBI (LODR) Regulations, 2015 (Statement Of Deviation Or Variation For Proceeds Of Public Issue, Rights Issue, Preferential Issue, QIP) For The Quarter Ended 30.06.2025.
2 Jul - No public, rights, preferential issue or QIP proceeds for quarter ended 30.06.2023.
-
Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (LODR, Regulation 2015) For The Quarter Ended 30-6-2025.
2 Jul - Company claims exemption from related party transaction disclosures for Q1 FY2025-26.
- Closure of Trading Window 30 Jun
- Closure of Trading Window 30 Jun
-
Announcement under Regulation 30 (LODR)-Change in Management
21 May - Appointment of Swapnil Madiyar as Non-Promoter, Non-Executive Additional Director, subject to AGM approval.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
http://www.colinz.com/about.html
CLL is a manufacturer and exporter of pharmaceutical formulations for allopathic, ayurvedic, nutraceticals in dosage forms of tablets, capsules, ointments, creams, granules, liquid, orals, injectables, syrups, suppsitories, etc. It also has certain specialized products for Gynaecology, cardiology, gastroenterology, etc.